Prosecution Insights
Last updated: November 20, 2026
Application No. 19/202,430

REVERSIBLE THERMAL NEUROMODULATION USING FOCUSED ULTRASOUND

Final Rejection §102§103§112
Filed
May 08, 2025
Priority
Sep 28, 2018 — provisional 62/738,420 +1 more
Examiner
NGANGA, BONIFACE N
Art Unit
3797
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Regents of the University of Minnesota
OA Round
2 (Final)
64%
Grant Probability
Moderate
3-4
OA Rounds
2y 0m
Est. Remaining
93%
With Interview

Examiner Intelligence

Grants 64% of resolved cases
64%
Career Allowance Rate
370 granted / 575 resolved
-5.7% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 6m
Avg Prosecution
22 currently pending
Career history
608
Total Applications
across all art units

Statute-Specific Performance

§101
4.6%
-35.4% vs TC avg
§103
46.0%
+6.0% vs TC avg
§102
14.7%
-25.3% vs TC avg
§112
28.3%
-11.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 575 resolved cases

Office Action

§102 §103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Response to Amendment This Office action is responsive to the amendment filed October 01, 2026. As directed by the amendment, claims 1, 13 and 17 have been amended. The amendment to claim 13 is sufficient to overcome the 35 U.S.C 101 rejection and 35 U.S.C 112(b) rejections of claim 13 from the previous Office action. Those rejection are hereby withdrawn. Response to Argument Applicant argues, in the paragraph bridging pages 7 and 8 of the response, that the general programmability of the field-programmable gate array (FPGA) disclosed in Li-2018 does not establish that the system is configured to deliver focused ultrasound for at least 150 seconds. Applicant further contends that the rejection merely establishes that the system could be modified to operate differently, which is insufficient to establish express or inherent disclosure. In response, Applicant's arguments are based on an incorrect interpretation of the claim limitation. As explained in the previous Office Action, the disputed "configured to" limitation is interpreted as functional language reciting a capability of the claimed system, rather than requiring actual performance of the associated operation. This interpretation is consistent with the Board Decision dated March 17, 2025, in parent application No. 16/586,357, at page 4, footnote 3, which expressly states: “3We note that Appellant's arguments related to the claimed method steps do not necessarily apply to the system of claim 11. This is because the "configured to" language in the system claim does not require the associated method step be performed. Rather, the "configured to" language is a recitation of intended use. A recitation of intended use in a claim must result in a structural difference over the prior art in order to overcome an anticipation rejection, and if a prior art structure is capable of performing the intended use, then it meets the claim. See In re Schreiber, 128 F.3d 1473, 1477 (Fed. Cir. 1997)”. “The ‘configured to’ language in the system claim does not require the associated method step be performed. Rather, the ‘configured to’ language is a recitation of intended use. A recitation of intended use in a claim must result in a structural difference over the prior art in order to overcome an anticipation rejection, and if a prior art structure is capable of performing the intended use, then it meets the claim. See In re Schreiber, 128 F.3d 1473, 1477 (Fed. Cir. 1997).” Applicant has not established that the disputed limitation requires any structural distinction over the system disclosed in Li-2018 or otherwise rebutted the Examiner's claim interpretation. Accordingly, the limitation is met by Li-2018. As set forth in the previous Office Action, Li-2018 discloses a system comprising a pulse generator that includes a field-programmable gate array (FPGA) (see the cited paragraph on page 1584). The FPGA provides programmability of the pulse generator, thereby rendering the system capable of delivering focused ultrasound for at least 150 seconds. Applicant's contention that the system "might be modified to operate differently" does not overcome the rejection. The Examiner's position is that the claimed system limitation recites a capability, not a requirement that the associated operation actually be performed. In view of the foregoing, and consistent with the Board's interpretation of the "configured to" language in the above-referenced decision, Applicant's arguments are not persuasive. Accordingly, the rejection is maintained for the reasons set forth in the previous Office Action New Rejections necessitated by Amendments Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claim 17 is rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 17 now recites that the controller is configured to determine ISPTA of the delivered focused ultrasound energy. However, while the disclose a method/process that include determination of ISPTA, and further discloses a controller (see e.g., cited portions of support of amendment in the response), there is no written description that the controller is configured to determine ISPTA as claimed. In view of these, the amendment to claim 17 fails to convey to those of ordinary skill in the art that the Applicant was in possession of the invention now claimed. Maintained Rejections Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 11 and 13-20 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Applicant cited Li et al., "Image-Guided Dual-Target Neuromodulation of the Mouse Brain Using Array Ultrasound" (“Li-2018”) as evidenced by Applicant cited Li et al., “Improved Anatomical Specificity of Nain-Invasive Neuro-stimulation by High Frequency (5MHz) Ultrasound” hereinafter “Li-2016”. Regarding claim 11, Li-2018 discloses system (page 1584, right column, first full paragraph and continuing to page 1585, Fig. 2 (a)) comprising: a dual-mode ultrasound transducer configured to deliver focused ultrasound energy; and a controller operably coupled to the dual-mode ultrasound transducer, the controller configured to drive the dual-mode ultrasound transducer to deliver focused ultrasound energy (page 1586. Fig. 5 text “Size of the acoustic focus of the dual-mode transducer”, see illustration Fig. 5(a), two focus locations are illustrated). In regards to the recitation to cause heating of target nervous system tissue for at least about 150 seconds tissue to reversibly modulate neural activity, this recitation is directed to functional language or a capability of the claimed system (i.e. effects imparted by the claimed system). it is to be noted here that the claims under examinations are directed to an apparatus (system). A claim term is functional when it recites a feature “by what it does rather than by what it is”. Additionally, “A functional limitation is often used in association with an element, ingredient, or step of a process to define a particular capability or purpose that is served by the recited element, ingredient or step. In Innova/Pure Water Inc. v. Safari Water Filtration Sys. Inc., 381 F.3d 1111, 1117-20, 72 USPQ2d 1001, 1006-08 (Fed. Cir. 2004) (MPEP 2173.05(g)). While features of an apparatus may be recited either structurally or functionally, claims directed to an apparatus must be distinguished from the prior art in terms of structure rather than function. See In re Schreiber, 128 F.3d 1473, 1477-78, 44 USPQ2d 1429, 1431-32 (Fed. Cir. 1997). In the instant case, the system of Li-2018 comprise a pulse generator that comprise a field-programmable gate array (FGPA) - see cited paragraph in page 1584, the system of Li-2018 is therefore programmable to deliver focused ultrasound for at least 150 seconds. In regards to cause heating of target nervous system tissue, in page 1588, paragraph bridging left and right column, with reference to Fig. 6, 5 Mhz ultrasound stimulation was applied; further, in page 1584, left column, third full paragraph, “This study is the first to utilize array technology specifically for dual-target neuromodulation in small animals. Our previous study successfully applied 5-MHz ultrasound for neuromodulation with improved anatomical specificity in the mouse brain [31]”. It is examiner’s position that ultrasound neuromodulation in Li-2018 would cause heating the target nervous tissue as citation 31 in Li-2018 discloses the effects of 5 MHz stimulation. Citations 31 is Li-2016, in page 5 of Li-2016, section titled “Evaluation of temperature and safety”,5Mhz stimulation is causes heating, in view of peak temperature of 1.6oC, and the teaching that the temperature may vary, by varying duration of stimulus. As such, the system of Li-2018 is capable of causing heating of target nervous tissue, by varying duration of the 5 Mhz ultrasound stimulus via the programmable (FPGA) pulse generator. Regarding claim 13, see 35 U.S.C 112(b) rejections above, in view of Li-2018, page 1584, the dual-mode transducer is capable of or is configured to be positioned outside of a subject’s skull. Regarding claims 14 and 15, see discussion in claim 11 above with reference to Li-2016, by adjusting the parameters of the programmable pulse generator, the delivered ultrasound energy will be configured to heat the target tissue to a temperature above 2oC and for a duration of at least 180 seconds as desired, i.e., the system of Li-2018 is configured i.e., programable, to adjust the parameters of the focused ultrasound energy to heat the nervous tissue more than 2 degrees or to deliver the focused ultrasound energy for at least 180 seconds, if desired. Regarding claims 16 and 18, these recitations are directed to a property of the focused ultrasound energy, examiner notes that the programmable pulse generator is programmable, hence configured to generate the property and/or effect of the focused ultrasound energy recited in the claims at the target nervous tissue, i.e., the pulse generator is programmable such that the ISPTA, at target nervous tissue will be above 0.3 W/cm2, the pulse generator is programmable such that the focused ultrasound energy will have a duty cycle of 10%, as these limitations are attributes to a property of the focused ultrasound energy that are adjustable by the programmable pulse generator. Regarding claim 17, in view of Li-2016, page 7, fifth paragraph regarding the 5 MHz neuromodulation being safe for brain tissue, infers that the ISPTA of the delivered focused ultrasound energy does not damage target nervous system tissue and the controller of Li-2018 is programmable to perform this function. Regarding claim 19, the carrier frequency of 5 MHz in LI-2018 as discussed in claim 11 above, is at least 1 Mhz. Regarding claim 20, see Fig. 5 in page 1586 of Li-2018, the depicted focal spots are less than 5 mm in at least two dimensions. Examiner further notes that the programmable pulse generator of Li-2018 is configured to adjust the focal spot to meet this claim limitation. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim 12 is rejected under 35 U.S.C. 103 as being unpatentable over Li-2018 as evidenced by Li-2016. Regarding claim 12, as discussed in claim 1 above, Li-2018 does not explicitly disclose at least one other dual-mode transducer to provide the focused ultrasound energy, however, at the time of filing the claimed invention, it would have been obvious to one having ordinary skill in the art at the time the invention was made to duplicate the dual-mode ultrasound transducer in order to perform the same function of the disclosed dual-mode transducer considering that it is well-known and common practice to use more than one ultrasound transducer to target a nerve tissue for stimulation, and/or since it has been held that mere duplication of the essential working parts of a device involves only routine skill in the art. St. Regis Paper Co. v. Bemis Co., 193 USPQ 8 MPEP 2144.04 (VI-B). Conclusion Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to BONIFACE N NGANGA whose telephone number is (571)270-7393. The examiner can normally be reached Mon. - Thurs. 5:30 am - 4:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, ANNE M KOZAK can be reached at (571) 270-0552. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /BONIFACE N NGANGA/Primary Examiner, Art Unit 3797
Read full office action

Prosecution Timeline

May 08, 2025
Application Filed
Jul 10, 2026
Non-Final Rejection mailed — §102, §103, §112
Oct 01, 2026
Response Filed
Nov 05, 2026
Final Rejection mailed — §102, §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12796930
MEDICAL IMAGE DIAGNOSTIC SYSTEM, OPERATION METHOD OF MEDICAL IMAGE DIAGNOSTIC SYSTEM, AND VIDEO DISPLAY SYSTEM
2y 6m to grant Granted Nov 17, 2026
Patent 12788368
SYSTEM
1y 8m to grant Granted Nov 10, 2026
Patent 12778500
ESTIMATING AN ACTUAL LIGHT PROFILE FOR AN INDIVIDUAL
2y 10m to grant Granted Nov 03, 2026
Patent 12778428
OPTICAL SENSOR FOR MONITORING TEMPERATURE-INDUCED CHANGES IN BIOLOGICAL TISSUES
2y 8m to grant Granted Nov 03, 2026
Patent 12773580
Cancer Imaging Methods And Cancer Treatment Methods Using Thermotherapy And Drug Delivery
2y 4m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
64%
Grant Probability
93%
With Interview (+28.6%)
3y 6m (~2y 0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 575 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month